F-Prime Capital

F-Prime Capital is a Cambridge, Massachusetts-based venture capital firm that has operated since 1969, making it one of the oldestVC firms in the country. The firm was originally founded as a private investment arm focused on healthcare and technology, and over five decades it has evolved into a globally recognized investor with over $4.8B in assets under management. Unlike mostVC firms that raise capital from outside limited partners, F-Prime has been entirely self-capitalized since its founding — a structural advantage that allows the firm to take long-term views on investments without LP pressure.

The firm's longevity and structure have produced one of venture capital's most distinctive track records: 52 IPOs and 400+ portfolio companies across healthcare, technology, and fintech. F-Prime has backed companies from their earliest stages — often before a product exists — and held positions through multiple decades of growth. This patient capital model is particularly powerful in life sciences, where development timelines stretch 10–15 years.

F-Prime's investment thesis centers on partnering with exceptional founders building world-changing companies in healthcare and technology. The firm takes a sector-deep approach, with partners who have backgrounds as scientists, physicians, engineers, and operators — not just financiers. This enables F-Prime to evaluate clinical data, understand platform technology potential, and assess commercial trajectories with a sophistication that most generalistVC firms cannot match.

What makes F-Prime particularly distinctive is its willingness to start companies from scratch. Over the firm's history, it has co-founded more than 35 portfolio companies — not just invested in them, but been involved in the formation, team assembly, and strategic development from day one. This company-building capability attracts founders who want a lead investor that will be genuinely hands-on from inception.

The firm's global footprint spans the Americas, Europe, and Asia, with particular strength in the US Northeast biotech corridor, the UK and European life sciences ecosystem, and select Asian markets. F-Prime's Asia presence gives portfolio companies meaningful leverage for cross-border expansion — a particular advantage for US biotech companies seeking to access Asian clinical markets or Asian enterprise software companies looking to expand westward.

F-Prime operates without outside LP capital, which means the firm doesn't face the redemption pressure that drives manyVC firms toward short-term thinking. This allows F-Prime to hold positions through market dislocations, support companies through difficult clinical or product phases, and make follow-on investments on timelines that suit the company rather than the fund.

F-Prime's investment approach is organized around two core verticals — life sciences and technology — with deep sector expertise in each. In life sciences, the firm invests across therapeutics, medtech, and biotech platform companies, with particular interest in modality-agnostic platform plays that can generate multiple pipeline candidates. In technology, F-Prime targets enterprise software, fintech infrastructure, and frontier technologies including crypto assets and decentralized systems.

The firm's life sciences thesis is built on the conviction that the intersection of biology and engineering is producing a new generation of medicine — gene editing, cell therapy, RNA therapeutics, and targeted protein degradation are all areas where F-Prime has established meaningful positions. The firm looks for companies with strong IP moats, clear clinical paths, and managements teams that combine scientific excellence with operational capability.

F-Prime's technology investing thesis centers on transformative infrastructure — companies that rebuild foundational layers of industries rather than building point solutions on top of legacy systems. Toast (restaurant technology), Flywire (payments infrastructure), and Benchling (life sciences R&D cloud) all reflect this conviction about platform over point solution.

The firm is notably sector-agnostic within its vertical scope — it will invest in a wide variety of industries as long as the team and technology meet its bar. F-Prime has made meaningful investments in agriculture tech, climate tech, construction tech, and insurance tech alongside its core healthcare and enterprise software positions.

F-Prime's company-building capability is a key differentiator. When the firm identifies an unmet need in a target market and cannot find an existing founder to back, it will actively assemble a founding team and co-found a company. This gives F-Prime optionality that mostVC firms don't have — and attracts founders who want a lead investor with both capital and operational capability.

The firm's lack of outside LP capital means investment decisions are made entirely by the partnership without external pressure. This enables F-Prime to hold positions through market dislocations and make follow-on investments on timelines that match company needs rather than fund life cycles.

F-Prime has maintained an active investment pace in 2024–2025, with particular focus on next-generation therapeutics modalities, AI-native enterprise software, and fintech infrastructure. The firm's life sciences team has been active in gene therapy and RNA therapeutics, where the combination of falling costs and expanding biological understanding is enabling new company formation.

In technology, F-Prime has invested in AI infrastructure and developer tooling companies, reflecting a conviction that the AI revolution will require entirely new infrastructure layers — from training data management to inference optimization to AI-native security. These investments are largely at the seed and Series A stage, where F-Prime can establish positions before valuations compress.

F-Prime has also continued its company-building approach, actively identifying white spaces in target markets where existing solutions are inadequate and founding new companies to address them. This activity is concentrated in life sciences and healthcare services, where F-Prime's deep domain expertise creates genuine insight into unmet needs.

The firm has supported existing portfolio companies through multiple financing rounds, including several significant follow-on investments in companies approaching clinical milestones or commercial inflection points. F-Prime's balance sheet allows it to participate in large rounds that would strain most seed-stageVC firms.

F-Prime's global network continues to drive deal flow from regions outside the US — particularly in European biotech and Asian enterprise software. The firm's reputation for being a true long-term partner is particularly valued in markets where US institutional capital can be impatient.

In a challenging 2024–2025 market, F-Prime has been selective but not passive. The firm has raised its bar for new investments but has not retreated from its core thesis. Companies meeting F-Prime's criteria for team quality, technological differentiation, and market significance continue to receive funding.

Beam Therapeutics, co-founded by F-Prime, is the leading gene editing company using base editing technology — a precision approach to DNA editing that allows single-letter changes in the genetic code without double-strand breaks. Beam has advanced multiple programs into clinical development for genetic diseases and cancer, and its platform continues to generate new pipeline candidates. F-Prime led the company's Series A and participated in every subsequent round.

Denali Therapeutics, co-founded by F-Prime, is a neurodegeneration company taking a precision medicine approach to diseases like Alzheimer's and Parkinson's. Denali's genetic insights-driven pipeline has produced multiple clinical-stage programs, and the company's collaborations with Biogen and others demonstrate the industry's confidence in its approach. F-Prime was instrumental in founding the company in 2015.

Toast, the restaurant management and payments platform, has become the dominant technology provider for independent restaurants in the US. Toast's end-to-end platform handles point-of-sale, payments, order management, and customer engagement for tens of thousands of restaurant locations. F-Prime led Toast's Series A and participated in the company's growth from early product to public company.

Flywire, the cross-border payments infrastructure company, solved the complex problem of international tuition, medical, and B2B payments by building a network that connects thousands of institutions globally. Flywire went public in 2021 and has continued to expand its platform into new payment verticals.

Benchling, the R&D cloud platform for life sciences, has become the standard software layer for biotech and pharmaceutical research organizations. Scientists use Benchling to design experiments, manage lab data, and collaborate across organizations — creating a durable platform play in a historically fragmented market.

Devoted Health, co-founded by F-Prime, is a Medicare Advantage insurance company that uses technology and data to deliver better care to seniors. The company's clinical-first approach to Medicare Advantage has driven rapid membership growth and demonstrated that better health outcomes and lower costs are compatible goals. Other notable holdings include Innovent Biologics (oncology, went public on HKEX), Carrot Fertility (healthcare), and Metsera (obesity/metabolic medicines).

F-Prime's evaluation criteria start with founder quality — specifically, founders with deep domain expertise who have operated at the frontier of their field. In life sciences, this means founders who have done foundational scientific work in their disease area and can articulate both the clinical mechanism and the commercial path. In technology, it means founders who have built similar systems before and understand the real complexity of what they're building.

Technology differentiation is non-negotiable. F-Prime does not invest in companies that are incrementally better than existing solutions — it wants genuine platform or modality advantage that creates durable competitive moats. In biotech, this means strong IP and a clear scientific differentiation. In enterprise software, it means a fundamentally better approach to solving a meaningful problem.

Market size matters, but not in the way it matters at mostVC firms. F-Prime is willing to invest in large markets, but it is equally willing to invest in focused niche markets that can support a substantial company. The firm's question is: can this company become category-leading in its market, and can that market support a meaningful outcome?

The firm's ability to contribute beyond capital is a factor in investment decisions. F-Prime looks for opportunities where its sector expertise, global network, and company-building capability can add meaningful value. Companies that need these resources — not just capital — are a particularly good fit.

F-Prime evaluates management team composition carefully, particularly in life sciences where clinical and regulatory expertise are as important as business acumen. The firm looks for balanced teams where scientific and operational leadership are both present.

For companies F-Prime is starting from scratch, the evaluation process is even more intensive — the firm identifies the unmet need, assesses the scientific feasibility, and then works to recruit the right founding team. This is a months-long process with no guarantee of outcome, but it produces companies that are exceptionally well-prepared from day one.

F-Prime responds best to warm introductions from within its existing portfolio company network or from trusted advisors who have worked with the firm before. Given the firm's sector depth, introductions from academic institutions, hospital systems, or enterprise software companies that F-Prime has backed carry significant weight.

Cold outreach to F-Prime is viable for companies clearly in the firm's thesis areas — life sciences or technology — and particularly for founders with exceptional credentials in their domain. The firm's team is small relative to its AUM, so cold outreach gets more careful review than at high-volume firms, but a generic pitch will not get a response.

F-Prime's website provides information about the firm's investment sectors but not specific deal criteria. Research on the firm's published portfolio and public statements from partners will give you the best sense of current interests and investment themes.

For life sciences companies, F-Prime's scientific team reviews are detailed and technical. Be prepared to present clinical data, mechanism of action, and competitive landscape analysis at a scientific level — the firm's partners will probe deeply on the biology. Business and commercial discussions come after scientific due diligence is complete.

For technology companies, F-Prime will focus on product architecture, engineering quality, and market competitive dynamics. The firm's partners have deep operating experience in enterprise software, so surface-level product demonstrations will not impress — come prepared to discuss the hard engineering trade-offs your team has made.

F-Prime's investment timeline varies significantly based on sector and stage. Life sciences investments involving clinical data review can take 3–6 months from first meeting to close. Technology investments at seed or Series A can move faster, sometimes closing in 4–8 weeks for straightforward deals.

F-Prime invests across the full lifecycle from company founding through growth stage, which means financial preparedness requirements vary significantly by stage and sector. At the earliest stages in life sciences, where there is often no revenue, F-Prime focuses on burn rate modeling, milestone planning, and path to next financing — not revenue projections.

For life sciences companies in clinical development, F-Prime expects founders to have detailed financial models that map clinical timelines, regulatory milestones, and capital requirements. The firm has seen enough biotech financings to know when projections are unrealistic, and will challenge assumptions rigorously.

For technology companies at Series A and beyond, F-Prime's evaluation includes detailed review of unit economics, cohort retention, customer acquisition cost trends, and net revenue retention. The firm's partners have operating backgrounds that make them difficult to impress with metrics that look good but don't reflect durable business quality.

F-Prime particularly values financial transparency — founders who can acknowledge where their model has uncertainty, articulate the key dependencies, and explain their contingency plans signal the kind of intellectual honesty the firm finds compelling. Founders who present only bullish scenarios lose credibility quickly.

For companies F-Prime is co-founding, the firm has extensive resources to help build financial infrastructure from scratch. This is one of the key advantages of the company's-building approach — founders get CFO-level support from day one.

Working with a fractional CFO is particularly valuable for companies at the Series B+ stage seeking growth capital from F-Prime. Having investor-quality financial statements, detailed financial models with multiple scenario analysis, and a clear capital allocation strategy makes a strong impression and accelerates due diligence.

F-Prime Capital's combination of sector depth, long-term capital, and company-building capability makes it one of the most distinctiveVC firms in healthcare and technology. For founders who are building genuinely novel solutions — whether in a lab or in code — F-Prime is often the ideal partner because it has the expertise, patience, and resources to support companies through the long journey from inception to category leadership.

Exploring other venture capital firms? Our comprehensive collection ofVC firm reviews covers hundreds of investors across all stages and sectors.

Each review provides detailed information about investment criteria, portfolio companies, and tips for securing funding.